193 related articles for article (PubMed ID: 12437373)
61. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
[TBL] [Abstract][Full Text] [Related]
62. Hypoxia stimulates p16 expression and association with cdk4.
Zygmunt A; Tedesco VC; Udho E; Krucher NA
Exp Cell Res; 2002 Aug; 278(1):53-60. PubMed ID: 12126957
[TBL] [Abstract][Full Text] [Related]
63. Cyclin D-dependent kinases, INK4 inhibitors and cancer.
Ortega S; Malumbres M; Barbacid M
Biochim Biophys Acta; 2002 Mar; 1602(1):73-87. PubMed ID: 11960696
[TBL] [Abstract][Full Text] [Related]
64. Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis.
Xia Y; Liu Y; Yang C; Simeone DM; Sun TT; DeGraff DJ; Tang MS; Zhang Y; Wu XR
Nat Commun; 2021 Apr; 12(1):2047. PubMed ID: 33824349
[TBL] [Abstract][Full Text] [Related]
65. Dissection of CDK4-binding and transactivation activities of p34(SEI-1) and comparison between functions of p34(SEI-1) and p16(INK4A).
Li J; Muscarella P; Joo SH; Knobloch TJ; Melvin WS; Weghorst CM; Tsai MD
Biochemistry; 2005 Oct; 44(40):13246-56. PubMed ID: 16201750
[TBL] [Abstract][Full Text] [Related]
66. CAK-independent activation of CDK6 by a viral cyclin.
Kaldis P; Ojala PM; Tong L; Mäkelä TP; Solomon MJ
Mol Biol Cell; 2001 Dec; 12(12):3987-99. PubMed ID: 11739795
[TBL] [Abstract][Full Text] [Related]
67. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation.
Dai CY; Furth EE; Mick R; Koh J; Takayama T; Niitsu Y; Enders GH
Gastroenterology; 2000 Oct; 119(4):929-42. PubMed ID: 11040180
[TBL] [Abstract][Full Text] [Related]
68. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
[TBL] [Abstract][Full Text] [Related]
69. Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors.
Mori N; Yang R; Kawamata N; Miller CW; Mizoguchi H; Koeffler HP
Int J Hematol; 2003 Apr; 77(3):259-62. PubMed ID: 12731669
[TBL] [Abstract][Full Text] [Related]
70. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons.
Wei G; Lonardo F; Ueda T; Kim T; Huvos AG; Healey JH; Ladanyi M
Int J Cancer; 1999 Jan; 80(2):199-204. PubMed ID: 9935200
[TBL] [Abstract][Full Text] [Related]
71. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
Lu H; Chang DJ; Baratte B; Meijer L; Schulze-Gahmen U
J Med Chem; 2005 Feb; 48(3):737-43. PubMed ID: 15689157
[TBL] [Abstract][Full Text] [Related]
72. cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain.
Grossel MJ; Baker GL; Hinds PW
J Biol Chem; 1999 Oct; 274(42):29960-7. PubMed ID: 10514479
[TBL] [Abstract][Full Text] [Related]
73. Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.
Mahajan A; Guo Y; Yuan C; Weghorst CM; Tsai MD; Li J
J Mol Biol; 2007 Nov; 373(4):990-1005. PubMed ID: 17881001
[TBL] [Abstract][Full Text] [Related]
74. Preimplantation-embryo-specific cell-cycle regulation is attributable to a low expression of retinoblastoma protein rather than its phosphorylation.
Egashira A; Kano K; Naito K
J Reprod Dev; 2011 Sep; 57(4):492-9. PubMed ID: 21519154
[TBL] [Abstract][Full Text] [Related]
75. Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes.
Holland EC; Hively WP; Gallo V; Varmus HE
Genes Dev; 1998 Dec; 12(23):3644-9. PubMed ID: 9851971
[TBL] [Abstract][Full Text] [Related]
76. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
[TBL] [Abstract][Full Text] [Related]
77. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.
Byeon IJ; Li J; Ericson K; Selby TL; Tevelev A; Kim HJ; O'Maille P; Tsai MD
Mol Cell; 1998 Feb; 1(3):421-31. PubMed ID: 9660926
[TBL] [Abstract][Full Text] [Related]
78. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Zhang B; Peng ZY
Biochemistry; 2002 May; 41(20):6293-302. PubMed ID: 12009890
[TBL] [Abstract][Full Text] [Related]
79. Compromising the constitutive p16
Kanugovi AV; Joseph C; Siripini S; Paithankar K; Amere SS
J Cell Biochem; 2020 Apr; 121(4):2770-2781. PubMed ID: 31692039
[TBL] [Abstract][Full Text] [Related]
80. Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4.
Warenius HM; Kilburn JD; Essex JW; Maurer RI; Blaydes JP; Agarwala U; Seabra LA
Mol Cancer; 2011 Jun; 10():72. PubMed ID: 21668989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
